The Osteoarthritis Research Society International (OARSI) held the 2017 OARSI World Congress in Las Vegas, April 27–30. Below, we report on two of the sessions held.
You Might Also Like
Explore This IssueAugust 2017
Retinoic Acid & Hand Osteoarthritis
Retinoic acid is a vitamin A derivative and hormonal signaling molecule with a role in cartilage and skeletal development. Retinoic acid has complex function, with prior studies implicating retinoids in osteoarthritis (OA) pathogenesis due to catabolic effects on mature cartilage, and other studies have harnessed the purported immunomodulatory effects of retinoids to delay the onset of experimental arthritis in animal models.1,2
In his plenary presentation titled, “Is Retinoic Acid a Target in Hand Osteoarthritis,” Helgi Jonsson, MD, PhD, of the University of Iceland, discussed work from Styrkarsdottir, et al, who identified a risk allele in the ALDH1A2 gene that increased the risk of severe hand OA by an OR of 1.48. The ALDH1A2 gene encodes retinaldehyde dehydrogenase 2 (RALDH2), the enzyme that converts retinaldehyde to retinoic acid.3 The association of ALDH1A2 and severe hand OA was first demonstrated in an Icelandic OA cohort and later replicated in British and Dutch cohorts. Interestingly no associations were seen with hip or knee OA.3
The risk allele is common, with around 77% of the population having one risk allele and 27% being homozygous.3 Since the risk allele confers reduced expression of ALDH1A2 and potentially retinoic acid, interest in retinoic acid as a treatment target in hand OA has increased. Although the teratogenicity of retinoids may be of less concern in the OA population, systemic toxicities and side effects are still limiting. Dr. Jonsson remarked that current treatment targets focus on inhibition of specific retinoic acid receptors.
Sarah Kingsbury, PhD, of the University of Leeds, U.K., gave a presentation on findings from the Hydroxychloroquine Effectiveness in Reducing Symptoms of Hand Osteoarthritis (HERO) trial.
Recent estimates place symptomatic hand OA as a more prevalent disease than symptomatic knee OA. Yet research often focuses on treatment for knee and hip OA. Hydroxychloroquine (HCQ) has been used to treat hand OA clinically; however, a paucity of well-developed trials support its use. The HERO trial aimed to close this gap with a multicenter, double-blind, randomized, controlled trial comparing HCQ with placebo in patients with symptomatic, radiographic hand OA with inadequate response to acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs) and opioids.4